292 related articles for article (PubMed ID: 6270303)
1. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Aiken JW; Shebuski RJ; Miller OV; Gorman RR
J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
[No Abstract] [Full Text] [Related]
2. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
[No Abstract] [Full Text] [Related]
3. Pharmacology of thromboxane synthetase inhibitors.
Aiken JW
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():253-8. PubMed ID: 6221532
[No Abstract] [Full Text] [Related]
4. Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
Shikano M; Ogawa K; Ito T; Chen LS; Ito Y; Imaizumi M; Uno T; Tsutsumi S; Satake T
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():375-7. PubMed ID: 3159226
[No Abstract] [Full Text] [Related]
5. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis].
Varfolomeev SD; Lakin KM; Mevkh AT; Novikova NV; Rukazenkov IuZ
Dokl Akad Nauk SSSR; 1985; 282(1):194-6. PubMed ID: 3928305
[No Abstract] [Full Text] [Related]
6. Modulation of human platelet function by prostacyclin and thromboxane A2.
Gorman RR
Fed Proc; 1979 Jan; 38(1):83-8. PubMed ID: 215465
[No Abstract] [Full Text] [Related]
7. Effects of selective thromboxane synthetase inhibitor and indomethacin on prostacyclin and thromboxane A2 from ischemic canine heart.
Ogawa K; Sakai K; Ito T; Watanabe J; Satake T
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():371-6. PubMed ID: 6221548
[No Abstract] [Full Text] [Related]
8. Blockage of partially obstructed coronary arteries with platelet thrombi: comparison between its prevention with cyclooxygenase inhibitors versus prostacyclin.
Aiken JW; Shebuski RJ; Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 7():635-9. PubMed ID: 6245568
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
10. Stimulation of vessel wall prostacyclin by selective thromboxane synthetase inhibitor OKY 1581.
Mehta J; Mehta P; Ostrowski N
Prostaglandins Leukot Med; 1983 Sep; 12(1):49-52. PubMed ID: 6356153
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of prostaglandin, prostacyclin, and thromboxane synthesis.
Vane JR
Adv Prostaglandin Thromboxane Res; 1978; 4():27-44. PubMed ID: 417572
[No Abstract] [Full Text] [Related]
12. Effects of thromboxane synthetase inhibitors on cyclical reduction of coronary blood flow in dogs.
Uchida Y; Murao S
Jpn Heart J; 1981 Nov; 22(6):971-5. PubMed ID: 7040725
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary vascular responses to thromboxane A2 as unmasked by OKY-1581. A novel inhibitor of thromboxane synthesis.
Kadowitz PJ; Nandiwada PA; Spannhake EW; Rosenson RS; McNamara DB; Hyman AL
Chest; 1983 May; 83(5 Suppl):72S-74S. PubMed ID: 6404609
[No Abstract] [Full Text] [Related]
14. Comparative study of prostaglandin I2 (PG I2) and thromboxane A2 (TXA2) synthetase inhibitor (OKY-1581) on hemodynamics in pregnant dogs.
Murayama K; Kasai H; Adachi T; Utsunomiya O; Ouchi H
Nihon Sanka Fujinka Gakkai Zasshi; 1983 Mar; 35(3):344-50. PubMed ID: 6339650
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.
Mullane KM; Fornabaio D
Circ Res; 1988 Apr; 62(4):668-78. PubMed ID: 3127073
[TBL] [Abstract][Full Text] [Related]
16. The action of cyclooxygenase and prostacyclin-synthetase inhibitors on platelet-vessel wall interaction.
Bourgain RH; Six F; Andries R
Artery; 1980; 8(1):96-100. PubMed ID: 6775620
[TBL] [Abstract][Full Text] [Related]
17. Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog.
Shea MJ; Driscoll EM; Romson JL; Pitt B; Lucchesi BR
Eur J Pharmacol; 1984 Oct; 105(3-4):285-91. PubMed ID: 6542526
[TBL] [Abstract][Full Text] [Related]
18. The role of prostacyclin in vascular tissue.
Moncada S; Vane JR
Fed Proc; 1979 Jan; 38(1):66-71. PubMed ID: 215463
[TBL] [Abstract][Full Text] [Related]
19. In vivo inhibition of thromboxane synthetase in infarcted canine myocardium.
McCluskey ER; Kramer JB; Corr PB; Needleman P
Biochem Biophys Res Commun; 1984 Jun; 121(2):552-7. PubMed ID: 6539597
[TBL] [Abstract][Full Text] [Related]
20. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
Gorman RR; Fitzpatrick FA; Miller OV
Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
